Welcome to our dedicated page for Estrella Immunopharma news (Ticker: ESLA), a resource for investors and traders seeking the latest updates and insights on Estrella Immunopharma stock.
Estrella Immunopharma, Inc. (NASDAQ: ESLA) is a clinical-stage biopharmaceutical company developing CD19- and CD22-targeted ARTEMIS® T-cell therapies for cancers and autoimmune diseases. The ESLA news feed highlights company announcements that shed light on its clinical progress, financing activities, and Nasdaq listing status, which are key considerations for investors and observers following this biotechnology stock.
Much of Estrella’s recent news flow centers on EB103, its CD19-redirected ARTEMIS® T-cell therapy being evaluated in the STARLIGHT-1 Phase I/II trial in relapsed or refractory B-cell non-Hodgkin’s lymphoma. Press releases describe completion of dose cohorts, favorable safety data with no treatment-related serious adverse events in reported groups, and recommendations from an independent Data Safety Monitoring Board to advance the trial into Phase II at the Recommended Phase II Dose. Updates also cover activation of additional clinical sites, such as UC Davis Comprehensive Cancer Center and Baylor Scott & White Research Institute, and early response data in high-risk patient populations.
In addition to clinical milestones, ESLA news includes capital markets transactions such as private placements, PIPE financings, and registered direct offerings of common stock, pre-funded warrants, and common warrants. Estrella states that it intends to use net proceeds from these financings, together with existing cash, for general corporate purposes, working capital, and to support its STARLIGHT-1 trial and broader development plans. The company has also reported Nasdaq notifications regarding non-compliance and subsequent regaining of compliance with listing standards.
By reviewing Estrella Immunopharma news, readers can follow developments in its ARTEMIS® T-cell platform, track the evolution of the STARLIGHT-1 trial, and monitor corporate and listing updates that may influence perceptions of ESLA as a clinical-stage biotechnology issuer. Investors and stakeholders may wish to revisit this page regularly for the latest company-issued press releases and related coverage.
Estrella Immunopharma (Nasdaq: ESLA) presented updated STARLIGHT-1 Phase I data showing promising clinical activity for EB103, a CD19-redirected ARTEMIS T-cell therapy, in aggressive B-cell non-Hodgkin lymphoma.
Key highlights: 100% complete response (CR) in the high-dose cohort at Month 1 (all CRs remain through data cutoff), response durations of 3–18 months with median DOCR not yet reached, one complete responder with PCNSL, and no treatment-related serious adverse events reported in the nine-patient cohort.
Estrella Immunopharma (Nasdaq: ESLA) announced a late-breaking oral presentation of Phase 1 STARLIGHT-1 data for EB103 at the 2026 ASTCT & CIBMTR Tandem Meetings. The presentation (Final Paper LBA-1, Abstract 29644) is scheduled for Feb 7, 2026, 3:15 p.m. MST and the abstract will be posted Feb 4, 2026 at 12:00 a.m. CT.
Presenting author: Naseem Esteghamat, MD MS. The study evaluates CD19-redirected ARTEMIS T cells in aggressive B-cell non-Hodgkin lymphoma.
Estrella Immunopharma (NASDAQ: ESLA) closed a registered direct offering and a concurrent private placement on January 6, 2026, raising approximately $8.0 million aggregate gross proceeds.
The company issued 4,063,290 common shares and 1,000,000 pre-funded warrants; it also issued common warrants to purchase up to 7,594,935 shares. The combined price per share with warrant was $1.58 (pre-funded $1.57999). Pre-funded warrants carry a $0.00001 exercise price and no expiration; common warrants have a $1.39 strike and five-year term. Net proceeds are planned for general corporate purposes and to advance the lead program, EB103, through Phase II.
Estrella Immunopharma (NASDAQ: ESLA) announced definitive agreements for a registered direct offering and a concurrent private placement, together expected to raise approximately $8.0 million. The transaction, priced at-the-market under Nasdaq rules, consists of 5,063,290 Common Units (or Pre-Funded Units) and a total of 7,594,935 PIPE Common Warrants, each exercisable at $1.39. The offering price per Common Unit is $1.58 (Pre-Funded Unit: $1.5799). The Pre-Funded Warrants are immediately exercisable. Closing is expected on or about January 6, 2026. Net proceeds will be used for general corporate purposes and working capital; Aegis Capital is sole placement agent.
Estrella (NASDAQ: ESLA) announced an independent DSMB recommended advancing the STARLIGHT-1 trial of EB103 into Phase II at the Recommended Phase II Dose (RP2D).
The Phase I dose‑escalation (n=9) reported no treatment-related serious adverse events and the high‑dose cohort achieved a 100% complete response (CR) rate at Month 1 in all evaluable patients, including high‑risk subjects such as one with CNS lymphoma. The expansion phase will evaluate safety and preliminary efficacy at RP2D across multiple centers and inform the pivotal trial strategy (NCT06343311).
Estrella Immunopharma (NASDAQ: ESLA) completed the second dose cohort of the Phase I portion of its STARLIGHT-1 Phase I/II trial of EB103, a CD19-redirected ARTEMIS T-cell therapy for advanced B-cell non-Hodgkin’s lymphoma.
Key results: the cohort achieved a 100% complete response (CR) rate at Month 1 in all evaluable patients, including a patient with CNS lymphoma, and no treatment-related serious adverse events were reported. A Data and Safety Monitoring Board will review cumulative data to determine the Recommended Phase II Dose (RP2D) before dose expansion. Trial identifier: NCT06343311.
Estrella Immunopharma (NASDAQ: ESLA) announced it has regained compliance with Nasdaq listing requirements after addressing prior deficiencies. The company said Nasdaq confirmed compliance with the minimum bid price requirement (Rule 5550(a)(2)) and the minimum market value of listed securities requirement (Rule 5550(b)(2)), and that both matters are closed.
The company attributed the outcome to successful efforts to improve its balance sheet, including raising new capital to continue development of its CD19 and CD22-targeted ARTEMIS T-cell therapies. The Nasdaq letters were received on September 23, 2025, with the compliance status disclosed in an 8-K filed on September 29, 2025.
Estrella Immunopharma (NASDAQ: ESLA) has initiated dosing of the first patient in the second cohort of its Phase I/II STARLIGHT-1 trial, evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy for Advanced B-Cell Non-Hodgkin's Lymphomas (NHL). The second cohort will test a higher dose level following successful safety data from the first cohort, where no dose-limiting toxicities or treatment-related serious adverse events were observed.
The company's CEO, Cheng Liu, highlighted that EB103 shows promise in addressing limitations of traditional CAR-T therapies, particularly for high-risk patients with HIV-associated lymphoma and central nervous system lymphoma, who are typically excluded from existing CAR-T treatments.
FAQ
What is the current stock price of Estrella Immunopharma (ESLA)?
What is the market cap of Estrella Immunopharma (ESLA)?
